HR Execs on the Move

Open Book Extracts

www.openbookextracts.com

 
Headquartered in Roxboro, N.C., Open Book Extracts is a cGMP-certified manufacturer of premium plant-based cannabinoid products, aiming to be the industry`s true north by delivering premium products, exceptional service, and industry-leading transparency. With control of the entire supply chain, a state-of-the-art extraction campus near North Carolina`s Research Triangle, proprietary refinement and conversion methods backed by a growing IP portfolio, and a team of PhD chemists and seasoned business leaders, OBX is the trusted partner for global brands seeking to enter the marketplace. OBX Asia, with its headquarters in Hong Kong, provides strategic guidance and on-the-ground support for our Asia customers. ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Allen Olson
 Vice President of Supply Chain Profile
David Temelkoff
 Director of R&D and Quality Control Profile
David Temelkoff
 Vice President of Research and Development and Quality Control Profile
Andrea Baillo
 Vice President, Research and Product Innovation Profile
Andrea Groncy
 Senior Director of Project Management and Sales Profile

Similar Companies

Clark County Health Department

Clark County Health Department is a Martinsville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ogden Regional Medical Center

Ogden Regional Medical Center is a Ogden, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthnation

Healthnation, Inc. is a Lisle, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Healthcare Strategy Institute

Healthcare Strategy Institute is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.